Latest Oxygen Biotherapeutics (OXBT) Headlines
Post# of 58
Posted On: 03/13/2014 12:51:43 AM
Latest Oxygen Biotherapeutics (OXBT) Headlines
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
WEALTHMAKERS.COM Issues Report on Oxygen Biotherapeutics
M2 - Thu Mar 06, 7:27AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Oxygen Biotherapeutics (NASDAQ: OXBT). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.12 and the projected fundamental target of $10.50 per share.
Technical Notes on Top Gainers: Vipshop Holdings, Oxygen Biotherapeutics, JinkoSolar Holding, SunPower and BPZ Resources
PR Newswire - Wed Mar 05, 9:18AM CST
The US markets saw a positive sentiment on Tuesday, March 04, 2014, as the NASDAQ Composite closed at 4,351.97, climbing 1.75%, the Dow Jones Industrial Average ended the session at 16,395.88, up 1.41% and the S&P 500 edged 1.53% higher to finish the bullish trading session at 1,873.91. During the session healthy gains in the Financial, Health Care and Materials sectors positively impacted the broader market. A number of stocks saw large movements, including Vipshop Holdings Ltd (NYSE: VIPS), Oxygen Biotherapeutics Inc. (NASDAQ: OXBT), JinkoSolar Holding Company Ltd (NYSE: JKS), SunPower Corporation (NASDAQ: SPWR), and BPZ Resources Inc. (NYSE: BPZ), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Tue Mar 04, 7:01AM CST
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has been notified by the U.S. Food and Drug Administration (the "FDA") that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte(R). Lifting of the clinical hold clears the company to proceed with the clinical development program in the US. The FDA communicated this information to the company during a conference call with the FDA on Friday, February 28, 2014. Written confirmation of the FDA's decision is expected to be received within 30 days.
5 Stocks Ready to Explode Higher
at The Street - Wed Feb 26, 2:03PM CST
Here's a look at five stocks with potentially explosive chart patterns.
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Newly Published Cardiac Surgery Study Provides Further Evidence that Levosimendan Significantly Improves Post-operative Kidney Function.
Business Wire - Thu Feb 13, 7:00AM CST
Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that a recently published study in the Journal of Cardiothoracic and Vascular Anesthesia provides evidence that levosimendan provides significant renal benefits to patients undergoing mitral valve surgery. The study was a double blinded, randomized, controlled trial of 128 patients with low ejection fraction (EF<45%) undergoing mitral valve surgery. As the authors reference, patients with low ejection fraction undergoing mitral valve surgery are at risk for adverse outcomes, including a significant risk for acute kidney injury. A link to access "In Press" version of this publication is found here http://www.jcvaonline.com/article/S1053-0770(...9/fulltext
Staffordshire University: University Relocation Decision is in Best Interests of Students
Business Wire - Thu Jan 30, 1:35AM CST
Staffordshire University has announced plans to deliver the majority of its courses from one main campus in Stoke-on-Trent.
Nasdaq stocks posting largest percentage increases
AP - Wed Jan 22, 12:47PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 16, 12:57PM CST
These under-$10 stocks look ready to break out and trade higher from current levels.
Today's Dead Cat Bounce Stock Is Oxygen Biotherapeutics (OXBT)
at The Street - Tue Jan 14, 8:45AM CST
Trade-Ideas LLC identified Oxygen Biotherapeutics (OXBT) as a "dead cat bounce" (down big yesterday but up big today) candidate
Chartered Financial Analyst, Osman Ghani, Provides Price Target for Oxygen Biotherapeutics, Inc.
PR Newswire - Mon Jan 13, 6:00AM CST
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) has been chosen by CFA, Osman Ghani to feature in a extensive research report that covers key features of the bio-technology market, Porter's five forces, US FDA approval process, new acquisition and demand, capital structure, and value of the company. The comprehensive CFA research report on OXBT with a price target can be viewed in its entirety by using this link: http://bit.ly/CFAResearchReportOXBT copy and paste to browser may be required
5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.
Oxygen Biotherapeutics to Present at Two Upcoming Healthcare Investor Conferences
Business Wire - Tue Jan 07, 7:00AM CST
--Biotech Showcase(TM) 2014 on January 15th
Oxygen Biotherapeutics Announces Key Details of Phase 3 Trial Protocol for levosimendan
Business Wire - Mon Jan 06, 7:00AM CST
Oxygen Biotherapeutics, Inc. ("OBI") (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass." http://www.clinicaltrials.gov/ct2/show/NCT020...an&rank=12
Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
WEALTHMAKERS.COM Issues Report on Oxygen Biotherapeutics
M2 - Thu Mar 06, 7:27AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Oxygen Biotherapeutics (NASDAQ: OXBT). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.12 and the projected fundamental target of $10.50 per share.
Technical Notes on Top Gainers: Vipshop Holdings, Oxygen Biotherapeutics, JinkoSolar Holding, SunPower and BPZ Resources
PR Newswire - Wed Mar 05, 9:18AM CST
The US markets saw a positive sentiment on Tuesday, March 04, 2014, as the NASDAQ Composite closed at 4,351.97, climbing 1.75%, the Dow Jones Industrial Average ended the session at 16,395.88, up 1.41% and the S&P 500 edged 1.53% higher to finish the bullish trading session at 1,873.91. During the session healthy gains in the Financial, Health Care and Materials sectors positively impacted the broader market. A number of stocks saw large movements, including Vipshop Holdings Ltd (NYSE: VIPS), Oxygen Biotherapeutics Inc. (NASDAQ: OXBT), JinkoSolar Holding Company Ltd (NYSE: JKS), SunPower Corporation (NASDAQ: SPWR), and BPZ Resources Inc. (NYSE: BPZ), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Tue Mar 04, 7:01AM CST
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has been notified by the U.S. Food and Drug Administration (the "FDA") that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte(R). Lifting of the clinical hold clears the company to proceed with the clinical development program in the US. The FDA communicated this information to the company during a conference call with the FDA on Friday, February 28, 2014. Written confirmation of the FDA's decision is expected to be received within 30 days.
5 Stocks Ready to Explode Higher
at The Street - Wed Feb 26, 2:03PM CST
Here's a look at five stocks with potentially explosive chart patterns.
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Newly Published Cardiac Surgery Study Provides Further Evidence that Levosimendan Significantly Improves Post-operative Kidney Function.
Business Wire - Thu Feb 13, 7:00AM CST
Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that a recently published study in the Journal of Cardiothoracic and Vascular Anesthesia provides evidence that levosimendan provides significant renal benefits to patients undergoing mitral valve surgery. The study was a double blinded, randomized, controlled trial of 128 patients with low ejection fraction (EF<45%) undergoing mitral valve surgery. As the authors reference, patients with low ejection fraction undergoing mitral valve surgery are at risk for adverse outcomes, including a significant risk for acute kidney injury. A link to access "In Press" version of this publication is found here http://www.jcvaonline.com/article/S1053-0770(...9/fulltext
Staffordshire University: University Relocation Decision is in Best Interests of Students
Business Wire - Thu Jan 30, 1:35AM CST
Staffordshire University has announced plans to deliver the majority of its courses from one main campus in Stoke-on-Trent.
Nasdaq stocks posting largest percentage increases
AP - Wed Jan 22, 12:47PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
5 Stocks Under $10 Set to Soar
at The Street - Thu Jan 16, 12:57PM CST
These under-$10 stocks look ready to break out and trade higher from current levels.
Today's Dead Cat Bounce Stock Is Oxygen Biotherapeutics (OXBT)
at The Street - Tue Jan 14, 8:45AM CST
Trade-Ideas LLC identified Oxygen Biotherapeutics (OXBT) as a "dead cat bounce" (down big yesterday but up big today) candidate
Chartered Financial Analyst, Osman Ghani, Provides Price Target for Oxygen Biotherapeutics, Inc.
PR Newswire - Mon Jan 13, 6:00AM CST
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) has been chosen by CFA, Osman Ghani to feature in a extensive research report that covers key features of the bio-technology market, Porter's five forces, US FDA approval process, new acquisition and demand, capital structure, and value of the company. The comprehensive CFA research report on OXBT with a price target can be viewed in its entirety by using this link: http://bit.ly/CFAResearchReportOXBT copy and paste to browser may be required
5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.
Oxygen Biotherapeutics to Present at Two Upcoming Healthcare Investor Conferences
Business Wire - Tue Jan 07, 7:00AM CST
--Biotech Showcase(TM) 2014 on January 15th
Oxygen Biotherapeutics Announces Key Details of Phase 3 Trial Protocol for levosimendan
Business Wire - Mon Jan 06, 7:00AM CST
Oxygen Biotherapeutics, Inc. ("OBI") (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass." http://www.clinicaltrials.gov/ct2/show/NCT020...an&rank=12
Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
(0)
(0)Tenax Therapeutics Inc. (TENX) Stock Research Links
Scroll down for more posts ▼